Boston, MA 10/29/2013 (wallstreetpr) – Baxter International Inc. (NYSE:BAX) is primarily a health care company that specializes in treating hemophilia, immune disorders and trauma amongst others. It is involved in both drug development and manufacture. Trade-Ideas LLC is the analyst firm hat had identified Baxter International as a pre-market stock leader. The reason for categorizing this stock as a pre-market leader is its market performance as on Monday, October 28, 2013. Baxter had traded around 11,913 shares in its pre-market hours and saw a 3.7 % increase as the day closed.
Analyst coverage
Trade economists at TheStreet Quant Ratings give a “buy” rating for the stock. Their analysis is based on the recently revealed third quarter earnings. They opined that the company has strengthened itself in areas like revenue growth, increased operating margins and cash flows and expansion of businesses. The stock is in a good position as regards its market share price and is expected to rise along with the company’s growth. The current dividend yield of the company is 2.8% and the PE ratio is 17.8 which are why eleven analysts give it a “buy” rating, five give it a “hold” rating and none of them rate it as “sell”.
Europe gets a taste of Baxter’s Hemostat
Encouraged by the enormous response to the earnings report, the company starts its expansion plans right after the announcement by introducing its hemostat health care product, HEMOPATCH, in Europe. Bleeding during surgical procedures mostly turn out to be fatal which is why the achieving hemostasis (coagulating of blood) in such times is important. Baxter’s HEMOPATCH is a collagen-based hemostatic device that can safely be used in such procedures to control bleeding. The response for this product was very positive among all the health care professionals.
This company’s stock is a good buy right now as Baxter is poised to cash upon its strongly built customer relationship.
